Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.41 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990298 | 0.84 | MTOR (0.52) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL28938104 | 0.84 | MTOR (0.37) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL11901262 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL15332503 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL6876042 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL15329666 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL29935788 | 0.80 | KAT6A (0.44) | ALDH1A1KDM4ESMN1; SMN2MAPK1MTOR | |
| SCHEMBL23501178 | 0.77 | KCNJ1 (0.54) | ALDH1A1KDM4ESMN1; SMN2MAPK1KCNJ1 | |
| SCHEMBL11901066 | 0.77 | TDO2 (0.47) | ALDH1A1KDM4EMAPK1MTORRPTOR | |
| SCHEMBL21262496 | 0.77 | MAPT (0.44) | ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327078-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117263945-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-113316578-B | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230295174-A1 | SALT AND CRYSTAL FORM OF PYRIMIDINE COMPOUND, AND PREPARATION METHODS THEREFOR | ELLIPSES PHARMA LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20230295174-A1 | SALT AND CRYSTAL FORM OF PYRIMIDINE COMPOUND, AND PREPARATION METHODS THEREFOR | ELLIPSES PHARMA LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
| EP-3929198-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| CN-113316578-A | Heterocyclic compounds, pharmaceutical compositions containing them, processes for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | ALDH1A1 644/4885KDM4E 3993/4885SMN1; SMN2 2630/4885 |
| US-20230295174-A1 | SALT AND CRYSTAL FORM OF PYRIMIDINE COMPOUND, AND PREPARATION METHODS THEREFOR | WEE1, TYMP, TYMS | ALDH1A1 2148/4885KDM4E 3448/4885SMN1; SMN2 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.